Regulation of Thromboplastin Synthesis in Mouse Placental Cells In Vitro

Knut Dalaker; Hans Prydz

doi:10.1055/s-0038-1665322

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1983; 50(04): 831-834
DOI: 10.1055/s-0038-1665322

Original Article

Schattauer GmbH Stuttgart

Regulation of Thromboplastin Synthesis in Mouse Placental Cells In Vitro

Knut Dalaker

The Research Institute for Internal Medicine, University of Oslo, and the Animal Dept, and Dept, of Obstetrics and Gynecology, Rikshospitalet, Oslo, Norway

,

Hans Prydz

The Research Institute for Internal Medicine, University of Oslo, and the Animal Dept, and Dept, of Obstetrics and Gynecology, Rikshospitalet, Oslo, Norway

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Mouse placental cells are probably constitutive producers of the thromboplastin apoprotein in vitro. The effect of cyclic AMP- elevating compounds on their expression of thromboplastin activity has been studied. Dibutyryl cyclic AMP, the phosphodiesterase inhibitor Ro 20-1724 and the adenyl cyclase stimulator forskolin all decrease the synthesis of thromboplastin. Prostaglandin E₂ and the phosphodiesterase inhibitor butyl-methyl-xanthine have a biphasic dose dependent effect. A stimulation was observed at low concentrations, whereas higher doses decreased the synthesis of thromboplastin. Adrenaline had no effect. Combination of two compounds, each at maximally inhibiting concentration gave no significant additive inhibitory effect, showing that they probably act via the same pathway.

Keywords

Thromboplastin - Tissue factor - Placenta - Cyclic AMP - Adenyl cyclase stimulators - Phosphodiesterase inhibitors

PDF (458 kb)

Referenzen

References
1 Bonnar J. Blood coagulation and fibrinolysis in obstetrics. Clin Haematol 1973; 2: 213-233
2 Gjønnasss H, Fagerol MK. Studies on coagulation and fibrinolysis in pregnancy. Acta Obstet Gynecol Scand 1975; 54: 363-367
3 Gilabert J, Aznar J, Parrilla JJ, Regañon E, Vila V, Estelles A. Alterations in the coagulation and fibrinolysis system in pregnancy, labour and puerperium, with special reference to a possible transitory state of intravascular coagulation during labour. Thromb Haemostas 1978; 40: 387-396
4 Bjørklid E, Storm E, Prydz H. The protein component of human brain thromboplastin. Biochem Biophys Res Commun 1973; 55: 969-976
5 Bjørklid E, Storm E. Purification and some properties of the protein component of tissue thromboplastin from human brain. Biochem J 1977; 165: 89-96
6 Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9 (suppl) (Suppl. 27) 183
7 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
8 Schneider CL. The active principle of placental toxin: thromboplas-tin: its inactivator in blood: Antithromboplastin. Am J Physiol 1947; 149: 123-129
9 Nilsen PA. Hypofibrinogenemia in premature separation of the placenta. Acta Obstet Gynecol Scand 1963; 42 (suppl) (Suppl. 02) 96
10 Dalaker K, Kaplun A, Lyberg T, Prydz H. Synthesis of thromboplastin (Factor III) in mouse placental cells in vitro. Gynecol Obstet Invest 1983; 15: 351-361
11 Prydz H, Lyberg T. Effect of some drugs on thromboplastin (Factor III) activity of human monocytes in vitro. Biochem Pharmacol 1980; 29: 9-14
12 Lyberg T. Effect of cyclic AMP and cyclic GMP on thromboplastin (Factor III) synthesis in human monocytes in vitro. Thromb Haemos-tas 1983; 50: 804-809
13 Hvatum M, Prydz HStudies. Solubiliza-tion with sodium deoxycholate. Biochim Biophys Acta 1966; 130: 92-101
14 Markwell MA K, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in mem-brane and lipoprotein samples. Anal Biochem 1978; 87: 206-210
15 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
16 Van Sande J, Cochaux P, Dumont JE. Forskolin stimulates adenylate cyclase and iodine metabolism in thyroid. FEBS Letters 1982; 150: 137-141
17 Satoh K, Ryan KJ. Prostaglandins and their effects on human placental adenyl cyclase. J Clin Invest 1972; 51: 456-458
18 Ferre F, Breuiller M, Cedard L. Effects of prostaglandins on cyclic nucleotide phosphodiesterase activity in the human term placenta. Prostaglandins 1982; 23: 675-693
19 Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. Effect of xanthine derivetes on lipolysis on adenosine 3’, 5-monophosphate phosphodiesterase activity. Mol Pharmacol 1970; 6: 597-603
20 Wiqvist N, Lindblom B, Wikland M, Wilhelmsson L. Prostaglandins and uterine contractility. Acta Obstet Gynecol Scand 1983; supplll 3: 23-29
21 Willman EA, Collins WP. Distribution of prostaglandins E²and F^2αwithin the foetoplacental unit throughout human pregnancy. J Endo-crinol 1976; 69: 413-419
22 Grimes DA, Schulz KF, Cates Jr W, Tyler Jr CW. Midtrimester abortion by intraamniotic prostaglandin F_2α . Safer than saline Obstet Gynecol 1977; 49: 612-616
23 Dalaker K, Prydz H. The coagulation factor VII in pregnancy. Br J Haematol 1983. (in press)